Form 4: Akero CSO Sells Shares Post-Novo Nordisk Merger

Akero Therapeutics' Chief Scientific Officer, Timothy Rolph, disposed of common stock, restricted stock units, and stock options following the company's merger with Novo Nordisk A/S, receiving cash and contingent value rights.

Summary

• Timothy Rolph, Chief Scientific Officer of Akero Therapeutics, Inc. (AKRO), reported the disposal of his beneficial ownership in the company.
• The transactions occurred on December 9, 2025, coinciding with the effective time of the merger between Akero Therapeutics and Novo Nordisk A/S.
• Akero Therapeutics became a wholly-owned subsidiary of Novo Nordisk A/S.
• Rolph disposed of 238,339 shares of common stock and 43,810 restricted stock units (RSUs).
• He also disposed of 406,014 stock options with various exercise prices ranging from $19.87 to $42.95.
• For each share of common stock and RSU, Rolph received $54.00 in cash (Closing Consideration) and one contractual contingent value right (CVR) representing the right to receive an additional $6.00 in cash upon achievement of a specified milestone.
• For each stock option, whether vested or not, Rolph received a cash payment equal to the product of the excess of the $54.00 Closing Consideration over the option's per share exercise price, multiplied by the total number of shares subject to such option, plus one CVR for each share.

Sentiment

Score: 7

Explanation: The filing reports the completion of a merger where Akero Therapeutics was acquired by Novo Nordisk A/S, providing shareholders, including the reporting person, with a significant cash payment and a contingent value right. This represents a positive outcome for the company's equity holders.

Positives

• The merger consideration provided a fixed cash payment of $54.00 per share and an additional potential $6.00 per share via a CVR, offering a clear exit value for shareholders.
• The transaction represents a successful acquisition for Akero Therapeutics' shareholders, including its Chief Scientific Officer, realizing value from their equity holdings.

Risks

• The $6.00 per share contingent value right (CVR) payment is not guaranteed and is dependent on the achievement of a specified milestone, introducing an element of uncertainty for the full merger consideration.

Future Outlook

NA

Industry Context

The acquisition of Akero Therapeutics by Novo Nordisk A/S highlights the ongoing consolidation and strategic M&A activity within the biotechnology and pharmaceutical sectors, particularly for companies with promising therapeutic candidates. This merger allows Novo Nordisk to expand its pipeline, while Akero's shareholders realize value through the acquisition.

Stakeholder Impact

• Shareholders: Received cash consideration ($54.00 per share) and contingent value rights ($6.00 per share) for their shares, RSUs, and options, realizing value from their investment.
• Employees (specifically Timothy Rolph): His equity holdings were converted into cash and CVRs as part of the merger.

Key Dates

Keywords

Akero Therapeutics, AKRO, Novo Nordisk, Merger, Acquisition, Form 4, Insider Transaction, Timothy Rolph, Chief Scientific Officer, Common Stock, Restricted Stock Units, Stock Options, Contingent Value Right, CVR, Biotechnology, Pharmaceutical